Stock 600713 NANJING PHARMACEUTICAL COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

All News NanJing Pharmaceutical Company Limited

Equities

600713

CNE000000KV1

End-of-day quote Shanghai S.E.
Other stock markets
 18:00:00 2024-05-27 EDT 		5-day change 1st Jan Change
4.75 CNY -1.25% Intraday chart for NanJing Pharmaceutical Company Limited -3.26% -1.86%
05-28 Nanjing Pharmaceutical Issues 500 Million Yuan Ultra-Short-Term Bonds MT
04-29 NanJing Pharmaceutical Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Nanjing Pharmaceutical Issues 500 Million Yuan Ultra-Short-Term Bonds
MT
NanJing Pharmaceutical Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
NanJing Medical Plans to Issue Up to 6 Billion Yuan in Ultra Short-Term Bonds
MT
NanJing Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023
CI
NanJing Pharmaceutical Company Limited Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
NanJing Pharmaceutical Company Limited(XSSC:600713) added to S&P Global BMI Index
CI
NanJing Pharmaceutical Company Limited Reports Earnings Results for the Half Year Ended June 30, 2023
CI
NanJing Pharmaceutical Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
NanJing Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended December 31, 2022
CI
NanJing Pharmaceutical Company Limited entered into Framework Agreement to acquire 55% stake in Suzhou Tianqing Xingwei Pharmaceutical Co., Ltd., a 55% stake in Zhejiang Tianqing Zhongwei Pharmaceutical Co., Ltd., and a 100% of Lianyungang Chia Tai-Tianqing Pharmaceutical Co., Ltd.
CI
NanJing Pharmaceutical Company Limited Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
NanJing Pharmaceutical Company Limited Reports Earnings Results for the Half Year Ended June 30, 2022
CI
NanJing Pharmaceutical Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
NanJing Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended December 31, 2021
CI
NanJing Medical’s Controlling Shareholder Boosts Stake to 44.2% For $158 Million
MT
NanJing Pharmaceutical Company Limited announced that it has received CNY 997.999997 million in funding from Nanjing XinGong Investment Group Co., Ltd
CI
Sichuan Luyan Pharmaceutical Co., Ltd. agreed to acquire Sichuan Yatong Pharmaceutical Co., Ltd. from NanJing Pharmaceutical Company Limited for CNY 19.9 million.
CI
NanJing Pharmaceutical Company Limited Reports Earnings Results for the Nine Months Ended September 30, 2021
CI
NanJing Pharmaceutical Company Limited announced that it expects to receive CNY 999.999998 million in funding from Nanjing XinGong Investment Group Co., Ltd
CI
Nanjing Pharmaceutical Company Limited Reports Earnings Results for the Half Year Ended June 30, 2021
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 600713 Stock
  4. News NanJing Pharmaceutical Company Limited